Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
FLD
4751
Fold Holdings
FLD
$29.7M
| $26.3K | ﹤0.01% |
+10,087
| New | +$33.4K |
2025 Q4
0 quarters
|
|
4752
Navios Maritime Partners
NMM
$2.68B
| $26.1K | ﹤0.01% |
497
| – | – |
2025 Q2
2 quarters
|
|
4753
ProShares Bitcoin Strategy ETF
BITO
$1.73B
| $25.5K | ﹤0.01% |
2,101
+2,100
| +210,000% | +$32.9K |
2022 Q1
15 quarters
|
|
4754
Prelude Therapeutics
PRLD
$293M
| $24.9K | ﹤0.01% |
8,602
-110
| -1% | -$186 |
2022 Q1
15 quarters
|
|
4755
AllianzIM US Equity 6 Month Floor5 Apr/Oct ETF
FLAO
$9.37M
| $24.9K | ﹤0.01% |
875
-191
| -18% | -$5.38K |
2025 Q3
1 quarter
|
|
4756
AllianzIM U.S. Equity Buffer20 Jul ETF
JULW
$255M
| $24.7K | ﹤0.01% |
+632
| New | +$24.4K |
2025 Q4
0 quarters
|
|
|
SRG
4757
Seritage Growth Properties
SRG
$102M
| $24.6K | ﹤0.01% |
7,575
+5,717
| +308% | +$21.7K |
2025 Q1
3 quarters
|
|
|
BLSH
4758
Bullish
BLSH
$5.19B
| $24.4K | ﹤0.01% |
643
-33,770
| -98% | -$1.64M |
2025 Q3
1 quarter
|
|
|
FONR
4759
DELISTED
Fonar
FONR
| $24K | ﹤0.01% |
1,294
+1,291
| +43,033% | +$19.5K |
2025 Q3
1 quarter
|
|
|
TIGR
4760
UP Fintech Holding
TIGR
$748M
| $23.9K | ﹤0.01% |
2,500
-124,534
| -98% | -$1.19M |
2021 Q1
19 quarters
|
|
|
JFB
4761
DELISTED
JFB Construction Holdings
JFB
| $23.8K | ﹤0.01% |
+3,256
| New | +$25.8K |
2025 Q4
0 quarters
|
|
4762
PUT
D-Wave Quantum Inc
QBTS
$5.99B
| $23.5K | ﹤0.01% |
900
-107,100
| -99% | -$3.12M |
2025 Q3
1 quarter
|
|
|
NOA
4763
North American Construction
NOA
$328M
| $23.3K | ﹤0.01% |
1,620
+1,602
| +8,900% | +$22.8K |
2023 Q1
11 quarters
|
|
4764
TScan Therapeutics
TCRX
$21.7M
| $23.2K | ﹤0.01% |
23,196
+4,119
| +22% | +$5.96K |
2024 Q2
6 quarters
|
|
4765
Innovator US Equity Buffer ETF July
BJUL
$363M
| $22.7K | ﹤0.01% |
447
+290
| +185% | +$14.5K |
2024 Q3
5 quarters
|
|
4766
Gaotu Techedu
GOTU
$599M
| $22.2K | ﹤0.01% |
+9,566
| New | +$25.9K |
2025 Q4
0 quarters
|
|
4767
Northern Technologies International Corp
NTIC
$73.1M
| $21.9K | ﹤0.01% |
2,800
-7
| -0.2% | -$54 |
2024 Q2
6 quarters
|
|
4768
Tevogen Inc
TVGN
$45.5M
| $21.7K | ﹤0.01% |
1,312
+171
| +15% | +$4.45K |
2024 Q2
6 quarters
|
|
4769
Precision BioSciences
DTIL
$174M
| $21.7K | ﹤0.01% |
5,211
+4,827
| +1,257% | +$27.4K |
2019 Q2
26 quarters
|
|
4770
CALL
Ascendis Pharma A/S
ASND
$15B
| $21.3K | ﹤0.01% |
+100
| New | +$20.7K |
2025 Q4
0 quarters
|
|
|
MESO
4771
Mesoblast
MESO
$1.83B
| $21.3K | ﹤0.01% |
1,180
+639
| +118% | +$11K |
2024 Q4
4 quarters
|
|
4772
Innovator US Equity Ultra Buffer ETF August
UAUG
$246M
| $21.1K | ﹤0.01% |
528
-1,365
| -72% | -$54K |
2024 Q3
5 quarters
|
|
|
UHG
4773
DELISTED
United Homes Group
UHG
| $20.9K | ﹤0.01% |
13,391
+13,387
| +334,675% | +$26K |
2023 Q2
10 quarters
|
|
4774
Innovator US Equity Ultra Buffer ETF February
UFEB
$176M
| $20.6K | ﹤0.01% |
559
-3,240
| -85% | -$117K |
2025 Q2
2 quarters
|
|
4775
Innovator US Equity Ultra Buffer ETF April
UAPR
$159M
| $20.4K | ﹤0.01% |
623
-2,285
| -79% | -$74K |
2024 Q4
4 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.